Measurement of Tamoxifen and Endoxifen Concentrations via Liquid Chromatography-Tandem Mass Spectrometry to Assess Adherence and Optimal Concentrations in South Africans with Breast Cancer Participating in a Pilot Trial: A Short Communication

Authors:
Publisher website
Google Scholar
Abstract
Background: Breast cancer is a leading cause of cancer-related mortality in women globally. Breast cancer patients treated with tamoxifen demonstrate interpatient variability, with adherence challenges affecting up to 50% of patients by year 5, directly impacting the concentrations of the active metabolite of tamoxifen, namely endoxifen, and clinical outcomes. This pilot study evaluated the use of tamoxifen and endoxifen therapeutic drug monitoring (TDM) using liquid chromatography-tandem mass spectrometry in South African women. Methods: The authors enrolled 20 women with estrogen receptor–positive breast cancer who were treated with tamoxifen; performed TDM on them, and assessed their adherence using objective and subjective methods. Objective nonadherence was defined as tamoxifen plasma concentration P = 0.322). Based on a therapeutic threshold of 5.97 ng/mL, 20% (95% CI: 8.1%–41.6%) had subtherapeutic endoxifen concentrations. Conclusions: A liquid chromatography-tandem mass spectrometry method was developed and fully validated according to the ICH M10 guidelines to simultaneously provide objective adherence measurements and TDM in a pilot study. This method enables clinicians to verify medication compliance and determine therapeutic concentrations by quantifying both tamoxifen adherence and endoxifen concentration in a single analysis.
Funding Information
  • National Research Foundation (PMDS22052715222)
  • Cancer Association of South Africa (CANSA does not allocate formal grant numbers for funding awards)

This publication has 25 references indexed in Scilit: